Name | CEP-9722 |
---|
Description | CEP-9722, the prodrug of CEP-8983, is a selective and orally active PARP-1 and PARP-2 inhibitor with IC50s of 20 nM and 6 nM, respectively. CEP-9722 has anticancer effects[1][2]. |
---|---|
Related Catalog | |
Target |
PARP-1:20 nM (IC50) PARP-2:6 nM (IC50) |
In Vivo | CEP-9722 (100-200 mg/kg/day; oral gavage; once daily; for 5 days a week for 4 weeks) shows dose-dependent antitumor activity in RT4 xenografts; 200 mg/kg daily is better than control and 100 mg/kg is not[1]. Animal Model: Nude mice bearing subcutaneous RT4 human urothelial carcinoma (UC) tumors[1] Dosage: 100 or 200 mg/kg/day Administration: Oral gavage; once daily; for 5 days a week for 4 weeks Result: Showed dose-dependent antitumor activity in RT4 xenografts. |
References |
Molecular Formula | C24H26N4O3 |
---|---|
Molecular Weight | 418.49 |